DrugMonitor™ Anti-Bivatuzumab Antibody (VS-1224-YC205)
CAT#: VS-1224-YC205
Bivatuzumab (formerly BIWA 4) is a humanized monoclonal antibody against CD44 v6. The DrugMonitor™ Anti-Bivatuzumab Antibody (VS-1224-YC205) is an anti-drug antibody (ADA) against Bivatuzumab. This drug-based antibody is raised in mice immunized with the Bivatuzumab. The anti-Bivatuzumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Bivatuzumab in samples.
Specifications
- Host Animal
- Mouse
- Specificity
- Bivatuzumab
- Target
- Bivatuzumab
- Immunogen
- Bivatuzumab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Bivatuzumab
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for VS-1224-YC205. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "bivatuzumab"
Anti-CD44 Recombinant Antibody (Bivatuzumab)Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6. It has been chemically linked to various radioisotopes for use in radiotherapy for, e.g. inoperable recurrent or metastatic head and neck cancer. It has also been linked to a cytotoxic drug mertansine to form bivatuzumab mertansine.
Afuco™ Anti-CD44 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-727)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. It is a humanized monoclonal antibody against CD44 v6.
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, Neut, FuncS
Application: WB, ELISA, IF
Application: ELISA, FuncS
Application: ELISA, FC, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
